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Abstract Anaphylaxis incidence rates and time trends in
the United States have been reported using different data
sources and selection methods. Larger studies using
diagnostic coding have inherent limitations in sensitivity
and specificity. In contrast, smaller studies using chart
reviews, including reports from single institutions, have
better case characterization but suffer from reduced external
validity due to their restricted nature. Increasing anaphy-
laxis hospitalization rates since the 1990s have been
reported abroad. However, we report no significant overall
increase in the United States. There have been several
reports of increasing anaphylaxis rates in northern popula-
tions in the United States, especially in younger people,
lending support to the suggestion that higher anaphylaxis
rates occur at higher latitudes. We analyzed anaphylaxis
hospitalization rates in comparably sized northern (New
York) and southern (Florida) states and found significant
time trend differences based on age. This suggests that the
relationship of latitude to anaphylaxis incidence is complex.
Keywords Anaphylaxis.Epidemiology.Population
based.Latitude.Time trend.ICD-9-CM code.Children.
Incidence
Introduction
Much that has been published under the category of the
epidemiology of anaphylaxis has been a description of the
syndrome as seen in specific practice venues, such as a
hospital or clinic [1, 2], rather than the study of anaphylaxis
in defined populations. Because of the infrequent occur-
rence of anaphylaxis and, until recently, the varying
definitions of the disorder, no anaphylaxis incidence studies
have been prospective cohort studies specific for anaphy-
laxis. As a result, a great deal remains to be learned about
the epidemiology of anaphylaxis.
A substantial portion of the existing data on the
epidemiology of anaphylaxis has come from investigations
that have limited scope population sources. Examples of
these studies include surveys [2, 3], the quality of which
depends on multiple factors, including the response rate, the
sample size, and especially selection bias. Other examples
of limited scope inquiries include voluntary registries [4, 5].
Registries are a representative source of epidemiologic data
only if the reporting of the condition is mandatory and the
data are validated.
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general populations and identify all or a known fraction of the
cases in a particular community [6, 7]. These studies allow
descriptive and analytic epidemiologic analyses to be
accomplished. Descriptive epidemiology denotes the exam-
ination of the frequency of a disease. Analytic epidemiology,
on the other hand, is concerned with testing hypotheses and
identifying the risk factors and causes of disease [7].
Examples of broad population-based studies include analy-
ses of nationwide/statewide hospital and vital statistics
databases [8]. Hospitalization registries use codes such as
International Classification of Diseases (ICD)-9 and ICD-10
to identify patients whose principal discharge diagnosis is
anaphylaxis. Investigations using these sources of data have
more external validity (ie, generalizability) than limited
scope studies. Anaphylaxis hospitalization studies have
involved primarily large administrative hospitalization data-
bases. These studies have been especially useful in charac-
terizing time trends, as clinical practice and principal
discharge diagnosis coding are unlikely to have changed
significantly during the study periods involved.
A weakness of such studies is that there is little or no
verification of the diagnosis. Therefore, there are attendant
risks of overdiagnosis and, especially, underrecognition.
This problem with internal validity is counterbalanced by a
greater generalizability due to the data coming from a broad
range of locations and other demographic characteristics.
Nonetheless, allergy researchers should strive to conduct
studies that have internal and external validity. Investiga-
tions that are free of bias (ie, systematic error) have internal
validity, whereas those whose results are generalizable have
external validity. These nationwide/statewide hospital
discharge databases probably are indicators of more
severe anaphylaxis. They do not include patients treated
for anaphylaxis as outpatients or as “treat-and-release”
emergency department (ED) patients. Anaphylaxis
patients seen in hospitals, EDs, health maintenance
organizations, and physicians’ practices also have been
identified using anaphylaxis ICD-9 coding as well as
diagnostic algorithms.
Chart review to identify cases has been used for case
verification and to estimate the sensitivity and specificity of
code-based case findings. Chart review studies can detail
organ/system involvement for anaphylaxis and allow for
identification of more cases, many of which are not
encountered in hospitalization or ED records. Thus, these
studies probably better characterize the overall incidence of
anaphylaxis. Chart reviews of community data indicate that
at least 39% of anaphylaxis cases are not treated as
inpatients [9]. The previous lack of consensus about the
definition/grading of anaphylaxis has added to the difficulty
in assessing and comparing studies and their case identifi-
cation methods [10].
Population-based Studies of Anaphylaxis
There are relatively few population-based studies of
anaphylaxis in the United States. The first such study
described anaphylaxis in the ED in the tertiary referral
hospital in Rochester, MN, which has a population of about
71,000 people [11]. ED visits were studied over a 4-month
period in 1993, and an incidence of 90 per 100,000 per year
based on presenting signs and symptoms was reported [11,
12]. A follow-up study by the same investigators encom-
passed a 5-year period (1983–1987) [12]. A total of 1255
medical records were reviewed for diagnoses suggestive of
anaphylaxis. These diagnoses included food allergy, drug
allergy, hypersensitivity not otherwise specified, adverse
effect of immunotherapy, adverse effect of injectable
diagnostic agent, subglottic or pharyngeal edema, bee sting
allergy, and unspecified allergic reaction. However, during
this 5-year period, only 154 anaphylactic episodes among
133 individual patients were identified. The average annual
incidence was 21 per 100,000 per year. Apartialexplanation
for the very high incidence reported in the 1993 study may be
thatthe data were obtained during the months of May through
August (Harduar-Morano, L., personal communication). The
incidence of anaphylaxis in Olmsted County, MN, from
1983 through 1987 was seasonally increased to a mean of 21
per month during July and August, as compared with an
incidence as low as 3 in April. Sixty-five of 133 cases (49%)
occurred during May through August [12]. If the incidence
were to be adjusted for the seasonal skewing of data, the
revised ED incidence would then be about two thirds as
much (ie, 60 per 100,000). This ED incidence is similar to
that reported for 2000 for all provider visits in a later
Olmsted County publication [13]. The major strength of
these first two studies is that this population is served by a
single medical system (the Mayo Clinic), which allows for
medical record review. Weaknesses include the relatively
small population and the limited demographic range of that
population. Unfortunately, a weakness of the third of the
Mayo Clinic studies is that the case finding methods are
unclear.
Population-based studies of larger populations have been
accomplished in the United Kingdom [14, 15]. This has
been facilitated by the National Health System, which
records disease information for the entire country. The
incidence of anaphylaxis in the United Kingdom has been
reported to be 8.4 per 100,000 in 1994 to 1999 [14] and 7.9
per 100,000 in 2005 [15]. This compares with the US
incidence in an HMO population of 19.1 per 100,000
(1996–2006) [16￿]. The strength of these reports is the large
population studied. The weakness is that these studies
depended on the lack of an accepted case definition and
diagnoses made by physicians who are not experts in
anaphylaxis. Weaknesses, such as lack of expert diagnosis
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Three population-based studies of anaphylaxis in Florida
have been conducted [8, 17￿, 18￿]. ED visits have been
assessed using both ICD-9-CM (Clinical Modification)
coding for an anaphylaxis diagnosis and an algorithm that
derives an anaphylaxis diagnosis on the basis of signs and
symptoms in patients for whom the treating physician did
not arrive at the diagnosis [18￿]. This study found an
incidence of ED visits of 3.3 per 100,000 persons per year
when anaphylaxis ICD-9-CM codingwas used. Anadditional
4.4 per 100,000 persons per year were identified using the
algorithm. Additional studies of essentially the same Florida
population found 2.8 hospital discharges for anaphylaxis per
100,000 population per year [8] and 5 anaphylactic deaths
per 10 million population per year [17￿].
This latter study determined the 10-year incidence of
death from anaphylaxis in Florida. Florida residents who
died from anaphylaxis from 1996 and 2005 were identified
from ICD-9 and ICD-10 codes on death certificates
statewide. Age, race, and gender-specific anaphylactic death
rates were calculated. There were 89 deaths. Decedents with
autopsy-confirmed diagnoses did not differ from those with
clinicaldiagnoseswithregardtorace,anaphylactictriggers,or
thepresenceofheartorlungdisease.Therelativeriskofdeath
from anaphylaxis was 14.09 for individuals 65 years of age
andolder(P=0.0000002) and 6.10 for people 35–64 years of
age (P=0.001)comparedwiththosewhowere5–14 years of
age. Deaths that occurred in EDs or outpatient settings were
2.11 times as likely to be anaphylactic deaths than deaths
that occurred in inpatient settings (P=0.0026). The ratios of
anaphylactic deaths to total deaths in March and April and in
July and August were greater than the ratios for the other
bimonthly periods (P=0.02).
The Mayo clinic studies—from a smaller population
base—reported one death from anaphylaxis during the 5-
year period from 1983 to 1987 [12] and no deaths during
the 10-year period from 1990 to 2000 [13]. These results
are essentially equivalent and not inconsistent with the
Florida finding of 0.05 deaths per 100,000 per year [17￿].
The British reports indicate 1.25–3.73 anaphylactic
deaths per 10 million per year [14, 19], which is consistent
with both the Florida and Minnesota mortality rates that are
based on ICD-9-CM coding for case finding. The twofold
higher rate of 11 per 10 million in Bern County, Switzerland,
may reflect fewer missed diagnoses [20].
Is the Prevalence of Anaphylaxis Increasing?
Increases in the anaphylaxis hospitalization rate have been
reported in the United Kingdom, United States, and
Australia. In Australia, the increased anaphylaxis hospital-
ization incidence was driven by hospitalizations in young
children (< 5 years of age), in whom food anaphylaxis was
the most common subset of anaphylaxis [21]. The
hospitalization rate in young children increased from 15
per 100,000 in 1993–1994 to 25 per 100,000 in 2004–2005
(8.8%/y), while the overall age-adjusted hospitalization rate
increased from less than 4 per 100,000 to 10 per 100,000.
In the United Kingdom, admission rates for anaphylaxis
rose sevenfold from 0.5 per 100,000 population in 1990–
1991 to 3.6 in 2003–2004, and increases were noted for all
age groups [22]. These data highlight large differences in
hospitalization rates in the different countries that may be
the result of different admission criteria as well as age
subset differences.
For this report, we determined the secular trend in
anaphylaxis discharges in the United States. Lin and Shah
[23] reported total hospitalizations for a principal diagnosis
of anaphylaxis due to food (ICD-9-CM 995.6), nonfood
anaphylaxis (ICD-9-CM 995.0), and anaphylaxis due to
serum (ICD-9-CM 999.4) for the years 1998 through 2005.
We calculated a population-based rate for the entire United
States using these data together with the respective yearly
US population estimates (Table 1). Year was treated as a
continuous exposure variable (independent variable) in a
negative binomial regression model. The relative rate (RR)
for the relationship between year and anaphylaxis hospital-
izations was 1.01, indicating a 1% increase in the rate for
each 1-year increase with anaphylaxis rates per 100,000,
rising from 2.1 to 2.3 (P=0.24 for the time trend).
There have been two more geographically limited US
reports of a secular increase in anaphylaxis. In one, the annual
incidence of anaphylaxis in Rochester, MN, is reported to
have increased modestly from slightly less than 50 per
100,000 in 1990 to 60 per 100,000 in 2000 (P=0.034) [13].
However, because of lack of clarity regarding the case
finding methods and the large year-to-year fluctuations in
anaphylaxis incidence reported, it is difficult to draw
conclusions regarding a secular trend from these data.
Interestingly, there was no increase in anaphylaxis from
1983 through 1987 in Olmsted County, MN [12]. The other
geographically limited study showed an increase in hospital-
izations in children in New York State from 1990 through
2006 [24]. Hospitalizations for anaphylaxis in adults were
not reported.
Because of these concerns, we decided to further test the
hypothesis that there has been a secular increase in
anaphylaxis in the United States. The New York State
findings in children were further assessed by adjusting the
case definition and repeating the analysis using New York
State and Florida databases [24]. New York and Florida
have similarly sized populations (15–20 million people).
Our new analysis was performed using negative binomial
regression models. Time trends were assessed by treating
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secondary discharge diagnosis fields were searched for the
following ICD-9-CM codes denoting anaphylaxis: 995.0,
995.6, and 999.4. The denominators for the anaphylaxis
hospitalization rates were the state resident population
estimates [25–27]. These analyses confirmed a statistically
significant increase in anaphylaxis hospitalizations for
individuals younger than 20 years of age from 1996 to
2005 in New York State (Fig. 1). That increase is from 2.1
to 3.7 per 100,000 per year. For each 1-year increase in
year, there was a 7% increase in the anaphylaxis hospital-
ization rate (P<0.0001) according to a negative binomial
regression model. However, between 1996 and 2005, there
were no statistically significant changes in the annual
anaphylaxis hospitalization rates among Florida children
(P=0.90). We also assessed hospitalizations for adults in
New York State and Florida for the same time periods.
There was a statistically significant increase in hospital-
izations for adults (> 19 years of age) from 1996 to 2005 in
New York. That increase is from 2.2 to 2.8 per 100,000 per
year. For each 1-year increase in year, there was a 2%
increase in the anaphylaxis hospitalization rate (P=0.04)
according to a negative binomial regression model. The
change in rates over time was different for adults and
children in New York State, as evidenced by a significant
interaction term that was created by multiplying the age
variable (children vs adults) by the year of discharge
variable (P=0.0008). In contrast to these results, there was
no increase in hospitalizations for anaphylaxis in Florida
from 1996 through 2005 for children (rates in both years,
1.3 per 100,000 per year; P=0.90) or adults (rates in both
years, 3.1 per 100,000 per year; P=0.10) (Fig. 1). In
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Fig. 1 Anaphylaxis hospitalization rates for residents of New York
and Florida between 1996 and 2005. Rates among New York children
and adolescents (NY-C) and New York adults (NY-A) are reported
along with rates among Florida children and adolescents (FL-C) and
Florida adults (FL-A). Children and adolescents were 0 to 19 years of
age, and adults were 20 years of age and older. Time trends were
evaluated by entering the discharge year as a continuous variable in
negative binomial regression models.
aThe P values are for change in
rate for each 1-year increase in discharge year from a negative
binomial regression model
Table 1 Number of hospitalizations due to anaphylaxis and annual rate in the United States (1998–2005)
a
Year Hospitalizations, n US population, n Rate per 100,000 population
1998 5583 270,248,000 2.07
1999 5863 272,691,000 2.15
2000 5938 282,171,957 2.10
2001 5681 285,081,556 1.99
2002 5907 287,803,914 2.05
2003 5807 290,326,418 2.00
2004 6365 293,045,739 2.17
2005 6670 295,753,151 2.26
aPrincipal diagnosis of anaphylaxis due to food (code 995.6*), nonfood anaphylaxis (code 995.0), or anaphylaxis due to serum (code 999.4) from Lin and
Shah [23]. Relative rate was 1.01 (P for the 1% increase in the anaphylaxis hospitalization rate for each increase of 1 calendar year, 0.24); from a negative
binomial regression model treating year as continuous independent variable
40 Curr Allergy Asthma Rep (2011) 11:37–44summary, significant time trends were detected in New
York State, but not in Florida.
An attractive explanation for the discrepancy between
the studies reporting an increasing incidence in anaphy-
laxis and our finding that there is no such increase is that
the reports showing an increase came from high latitude
states (New York and Minnesota). As we reported above,
there was no increase in Florida, which is a lower
latitude state. It is possible that the lack of a significant
increase in anaphylaxis hospitalizations nationally is due
to the increase in anaphylaxis hospitalizations in high
latitude states being offset by the lack of increase in
lower latitude states. This hypothesis, however, requires
further testing.
Influence of Latitude on Regional Differences
Regional differences in anaphylaxis-related clinical encoun-
ter and epinephrine prescription prevalence rates have
pointed toward an interesting north–south dichotomy. This
has led certain investigators to hypothesize a relationship
between vitamin D levels and anaphylaxis rates. In a 2004
US study, epinephrine autoinjector prescriptions were used
as a surrogate marker for anaphylaxis prevalence [28]. It
was found that 8–12 epinephrine autoinjector prescriptions
were issued per 1000 population in the New England states,
compared with only 2–3 per 1000 in many contiguous
southern and southwestern states (from California to
Mississippi). Multivariate adjustments for potentially con-
founding factors did not abrogate the significant difference
in epinephrine autoinjector prescriptions noted between the
New England states and the rest of the United States
(adjusted ORs, 3.55–4.07).
Some of these investigators then examined epinephrine
autoinjector prescriptions in 10 major areas in Australia
between 2006 and 2007 [29]. They found that stronger
geographic differences were noted for children 14 years of age
oryounger,andaninverserelationshipexistedbetweenlatitude
(which are negative numbers below the equator) and the
number of epinephrine autoinjectors per 100,000 population.
Multivariate adjustments failed to abrogate this relationship.
Australian hospitalizations for anaphylaxis between 2002 and
2007 did not, however, show a statistically significant
correlation with latitude.
ED visits for acute allergic reactions (a portion of which
were anaphylaxis) in the United States between 1993 and
2005 were also examined by this same team [30]. Compared
with the southern states, the Northeast had a modest increase
in acute allergic reactions (OR, 1.13; 95% CI, 1.01–1.27),
which was only apparent in a multivariate modeling (using
demographic factors only). Somewhat greater differences
were noted if only food-related allergic reactions were
analyzed (OR, 1.33; 95% CI, 1.14–1.56).
For this report, we decided also to examine regional
differences in anaphylaxis hospitalizations using Florida
and New York State inpatient discharge databases. We
examined regional and time trends in anaphylaxis hospital-
izations. Geographical and temporal associations were quan-
tified using RRs calculated from negative binomial regression
models that incorporated offset variables [31, 32]. Among
individuals 0–19 years of age, New York State residents
were twice as likely as Florida residents to be hospitalized
for anaphylaxis (unadjusted RR, 2.07; P<0.0001) (Table 2).
However, after adjusting for the year of discharge and a
state-of-residence-by-year-of-discharge interaction term, the
RR decreased to 1.38 (P=0.01). This association reversed
direction in individuals 20 years of age and older, with
Table 2 Unadjusted and adjusted relative rates for anaphylaxis hospitalization during the period 1996 to 2005 comparing New York State
residents with Florida residents
Variables(s) adjusted for: Age of residents
0–19 y ≥ 20 y
RR (NY vs FL)
a 95% CI P value RR (NY vs FL)
a 95% CI P value
(None) 2.07 1.74–2.47 <0.0001 0.67 0.63–0.73 <0.0001
Year of discharge
b 2.06 1.80–2.36 <0.0001 0.67 0.63–0.73 <0.0001
Year of discharge, and state-by-year interaction
c 1.38 1.07–1.79 0.01 0.57 0.49–0.65 <0.0001
aRRs are from negative binomial regression models and stratified by patient age (0–19 and ≥ 20 years). If adjustment for 1 or more variables resulted in a
state (NY vs FL) RR that deviated by ≥ 10% from the unadjusted state RR, then confounding was considered to be present and the adjusted RR was
emphasized
bYear was treated as a continuous variable, with 1 representing 1996, 2 representing 1997, and so forth
cA product interaction term was created by multiplying the state term (NYvs FL) by the year of discharge term. The interaction terms for the 0–19 and ≥ 20
age groups were statistically significant (P=0.001 and P=0.01, respectively)
FL—Florida residents; NY—New York State residents; RR—relative rate
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anaphylaxis hospitalization than older Floridians (adjusted
RR, 0.57; P<0.0001) (Table 2). Adults 20 years of age or
older were significantly more likely than children 0–19 years
of age to be hospitalized for anaphylaxis in Florida
(unadjusted RR, 2.67) (Table 3). The adjusted RR for
Florida adults versus Florida children did not deviate by
10% or more from the unadjusted RR after adjusting for the
year of discharge, or adjusting for both the year of discharge
and an interaction term [33]. Therefore, confounding by
these variables was considered to be absent, and the
unadjusted RR of 2.67 was the statistic of interest. In New
York State, adults 20 years of age or older were at a lower
risk of anaphylaxis hospitalization compared with children
0–19 years of age after adjusting for the year of discharge
(adjusted RR, 0.88; P=0.02), but not after adjusting for both
the year of discharge and the age-by-year interaction
(adjusted RR, 1.18; P=0.10) (Table 3).
Accuracy of the ICD-9-CM Coding of Anaphylaxis
The ICD-9-CM codes that include the word anaphylactic
are 995.0 (other anaphylactic shock not otherwise speci-
fied), 995.6 (anaphylactic shock due to adverse food
reaction), and 999.4 (anaphylactic shock due to serum not
otherwise specified). The ICD-10 codes that correspond to
these are T78.2, T78.0, and T80.5, respectively. There is an
additional ICD-10 code for anaphylactic shock due to
drugs, T88.6. ICD-9 codes that are commonly used to
identify anaphylaxis include shock due to anesthesia
(995.4) [9], dermatitis due to food taken internally
(693.1), toxic effect of venom (989.5), venomous bite or
sting (E905.9), and toxic effect of noxious substances eaten
as food (988.*). Use of additional anaphylaxis nonspecific
codes has enhanced sensitivity in case findings but at a cost
of decreased specificity.
Hospital discharge databases have served as a source of
health data for epidemiologic studies for many years [34].
The accuracy of the coding of both discharge diagnoses and
procedures in these databases has been debated and
evaluated by multiple investigators [34–38].
Two related concepts merit definition at this point:
accuracy and reliability. Accuracy is a measure of validity,
whereas reliability is a measure of reproducibility [39].
Reliability may be present even though validity is not.
Validation of the ICD-9-CM coding of anaphylaxis in hospital
inpatient and ED discharge databases would ideally proceed
as it has for other serious conditions [34, 37, 38]. First, a large
representative sample of records would be extracted. Second,
an accepted case definition would be identified as the gold
standard. Finally, data would be arranged in a contingency
table, and the sensitivity and specificity of the ICD-9-CM
coding of anaphylaxis as a principal or secondary discharge
diagnosis would be calculated using the accepted case
definition.
Klein and Yocum [11] conducted a retrospective
analysis of the ED records of all the patients who
presented to the ED of a rural tertiary care medical center
during a 4-month period. They identified 17 cases of
anaphylaxis. However, only four of the 17 patients had a
diagnosis of anaphylaxis. The authors concluded, “... most
of the cases in this study would have been unreported in
the International Classification of Diseases-ninth revision
nomenclature as anaphylaxis.”
Algorithms incorporating various ICD-9-CM codes have
been developed using South Carolina and Florida data to
better identify cases of anaphylaxis found in statewide ED
databases [18￿, 40]. The South Carolina study focused on
drug-related anaphylaxis in children and adolescents whose
Table 3 Unadjusted and adjusted relative rates for anaphylaxis hospitalization during the period 1996 to 2005 comparing adults 20 years of age
or older with children/adolescents 0 to 19 years of age
Variables(s) adjusted for: Florida residents New York State residents
RR (adults vs children)
a 95% CI P value RR (adults vs children)
a 95% CI P value
(None) 2.67 2.41–2.95 <0.0001 0.87 0.75–1.01 0.06
Year of discharge
b 2.67 2.42–2.94 <0.0001 0.88 0.79–0.98 0.02
Year of discharge, and age-by-year
interaction
c
2.87 2.32–3.55 <0.0001 1.18 0.97–1.43 0.10
aRRs are from negative binomial regression models and stratified by state of residence. If adjustment for 1 or more variables resulted in an RR (adults vs
children) that deviated by ≥ 10% from the unadjusted RR, then confounding was considered to be present and the adjusted RR was emphasized
bYear was treated as a continuous variable in which 1 represented 1996, 2 represented 1997, and so forth
cA product interaction term was created by multiplying the dichotomous age term (≥20 y vs 0–19 y) by the year of discharge term. The interaction term in
the Florida model was not statistically significant (P=0.45), but it was significant in the New York model (P=0.001)
RR—relative rate
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Room Hospital Discharge Database during the years 2000–
2002 [40]. The authors’ algorithm had a sensitivity of 100%
(95% CI, 79%–100%) and a specificity of 28% (95% CI,
16%–43%) when compared with their gold standard, which
was record review by two physicians.
The Florida team of researchers accessed statewide ED
data for the years 2005 and 2006 from the Florida Agency
for Health Care Administration [18￿]. Patients with ana-
phylaxis were identified using two methods: ICD-9-CM
codes specifically indicating anaphylaxis and an ICD-9-CM
algorithm based on the definition of anaphylaxis proposed
at the 2005 National Institute of Allergy and Infectious
Diseases and the Food Allergy and Anaphylaxis Network
symposium [10]. The algorithm identified anaphylaxis if
respiratory compromise or skin/mucosal involvement was
found in conjunction with shock due to anesthesia, if
respiratory compromise or reduced blood pressure was
found in conjunction with skin/mucosal involvement, or if
a combination of gastrointestinal symptoms and/or respira-
tory compromise and/or reduced blood pressure and/or skin/
mucosal involvement occurred in association with a potential
allergenic exposure. A total of 1149 patients were identified
using anaphylaxis ICD-9-CM codes, while 1602 patients
were identified with the algorithm. A total of 26 patients
were identified by both methods and were included in the
ICD-9-CM code total. The authors noted that the clinical risk
factors and the demographic features of the cases were
consistent between the two methods, although the algorithm
was more likely to identify older individuals (P<0.0001),
those with hypertension or heart disease (P<0.0001), and
individuals with venom-induced anaphylaxis (P<0.0001).
Conclusions
Population-based studies provide information on diseases in
defined populations. Accurate information regarding disease
incidence and description can beobtained ifthese populations
arelargeanddiverse.Population-basedstudiesofanaphylaxis
in the United States include those in Rochester, MN [11–13];
New York State [24]; and Florida [8, 17￿, 18￿]. We have
added new population-based analyses in this report. There
have been reports that the incidence of anaphylaxis has
manifested a secular increase in Australia, the United
Kingdom, and the United States [13, 21, 22]. We further
investigated this phenomenon and were able to confirm an
increase in anaphylaxis hospital discharges in New York
State, but not in Florida. This suggests an effect of latitude
on the increase in anaphylaxis. It had been previously
suggested that anaphylaxis is more prevalent in higher
latitudes. We found that children in New York State had a
higher incidence of hospital discharges for anaphylaxis than
children in Florida. However, the anaphylaxis hospital
discharge incidence for older individuals was greater in
Florida than in New York State. This indicates that the
relationship of latitude to the incidence of anaphylaxis is
more complex than initially proposed [28].
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